Telik Inc

Type: Company
Name: Telik Inc
Nationality: United States
Web Address: http://www.telik.com/
First reported May 18 2013 - Updated May 18 2013 - 1 reports

Form 4 TELIK INC For: May 15 Filed by: NEWMAN RICHARD B

StreetInsider.com - Form 4 TELIK INC For: May 15 Filed by: NEWMAN RICHARD B ... [Published Street Insider - May 18 2013]
Entities: Telik Inc
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Form 4 TELIK INC For: May 15 Filed by: CANTRALL EDWARD W

StreetInsider.com - Form 4 TELIK INC For: May 15 Filed by: CANTRALL EDWARD W ... [Published Street Insider - May 17 2013]
Entities: Telik Inc
First reported May 17 2013 - Updated May 17 2013 - 1 reports
Telik Inc
Telik Inc

Form 4 TELIK INC For: May 15 Filed by: GOLDRING STEVEN R

StreetInsider.com - Form 4 TELIK INC For: May 15 Filed by: GOLDRING STEVEN R ... [Published Street Insider - May 17 2013]
Entities: Telik Inc
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Telik, Inc. Announces First Quarter 2013 Financial Results

/PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or ... [Published BioSpace - May 13 2013]
Entities: Telik Inc
First reported May 11 2013 - Updated May 11 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ --$ Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013.$ The net loss for the quarter ended March$ 31,$ 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3$ million, ... [Published .NET Developer's Journal - May 11 2013]
First reported May 10 2013 - Updated May 10 2013 - 3 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ --$ Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013.$ The net loss for the quarter ended March$ 31,$ 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3$ million, ... [Published KGWN TV - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or ... [Published Rock Hill Herald - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, ... [Published Zecco - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ --$ Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31 , 2013.$ The net loss for the quarter ended March$ 31,$ 2013 was $1.9 million , or $0.46 per share, compared with a net loss of $2 .3$ million, ... [Published Barchart - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or ... [Published TickerTech.com - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

/PRNewswire/ -- Telik, Inc. (Nasdaq: TELK ) today reported financial results for the first quarter ended March 31 , 2013.  The net loss for the quarter ended March 31, 2013 was $1.9 million , or $0.46 per share, compared with a net loss of $2 .3 million, ... [Published Benzinga.com - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Telik Announces First Quarter 2013 Financial Results

PALO ALTO, Calif.Total research and development expenses (R&D) in the first quarter of 2013 were $0Total general and administrative expenses (G&A) in the first quarter of 2013 were $1Telik is currently focusing on the clinical development of its lead ... [Published ADVFN UK - May 10 2013]

Quotes

By EnhydrisPECorp : Yesterday, Enhydris correctly called the biotech Telik Inc. ( TELK ) a " perfect short candidate' once the stock crossed the $3.00 mark. Sure enough, TELK began to immediately show weakness at $3.03, and fell over 25% in a single day (including after hours trading). Our prediction was based on the underlying fundamentals and technicals of the stock, which clearly signaled that TELK represented an excellent shorting opportunity. Indeed, the biotech sector in general is rife with shorting opportunities due to explosive upside moves that are not supported by the company's fundamentals. Even so, shorting a biotech based on a quick run-up alone can be a fool's game. In this article, I explore the recent explosive run-up of Sangamo Biosciences, and discuss why shorting SGMO is a bad idea at this time. "
Sangamo BioSciences: A Biotech Not To Be Shorted [Published Healthcare Sector and Stocks Analysis from Seek... - Jan 15 2013]

More Content

All (41) | News (28) | Reports (3) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (6)
sort by: Date | Relevance
Form 4 TELIK INC For: May 15 Filed by: NEWMAN R... [Published Street Insider - May 18 2013]
Form 4 TELIK INC For: May 15 Filed by: CANTRALL... [Published Street Insider - May 17 2013]
Form 4 TELIK INC For: May 15 Filed by: GOLDRING... [Published Street Insider - May 17 2013]
Telik, Inc. Announces First Quarter 2013 Financ... [Published BioSpace - May 13 2013]
Telik Announces First Quarter 2013 Financial Re... [Published .NET Developer's Journal - May 11 2013]
Telik Announces First Quarter 2013 Financial Re... [Published KCOY 12 - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published KGWN TV - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published KGWN TV - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Bio-Medicine - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Sacramento Bee - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published StockHouse USA - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Sys-Con Australia - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Rock Hill Herald - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published I Stock Analyst - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Zecco - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Yahoo! Finance - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Barchart - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published TickerTech.com - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Reuters - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Benzinga.com - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published ADVFN UK - May 10 2013]
Telik Announces First Quarter 2013 Financial Re... [Published Financial Services - May 10 2013]
Alexza Pharmaceuticals, Inc. (ALXA): Watch This... [Published InsiderMonkey.com - May 08 2013]
Visit Malaysia for an idyllic honeymoon [Published It's your big day - May 02 2013]
Telik, Inc. (TELK) - Financial and Strategic SW... [Published TransWorldNews - Apr 21 2013]
Research and Markets: Mantle Cell Lymphoma - Pi... [Published Business Wire - Apr 18 2013]
Mantle Cell Lymphoma - Pipeline Review, H1 2013... [Published Individual.com - Apr 18 2013]
Mantle Cell Lymphoma - Pipeline Review, H1 2013... [Published PredictWallStreet - Apr 18 2013]
Visit Malaysia for a luxury break or an idyllic... [Published Easier - Apr 16 2013]
Telik: A Possible Investment, But Only After Mu... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 05 2013]
1 2
In Focus
  •  
Mikael Dolsten, Martin Brown, Rick Barry, [more]
  •  
Johnson & Johnson, Coronado Biosciences Inc, Sangamo BioSciences Inc, [more]
  •  
US Securities and Exchange Commission, FDA Food & Drug Administration, American Society of Hematology, [more]
  •  
Myelodysplastic Syndromes, Research & Development, Drugs, [more]
  •  
Yervoy, Metformin
  •  
Kuala Lumpur, Boston (Massachusetts, United States), Atlanta, [more]
  •  
Malaysia, United States, United Kingdom
  •  
Diseases, Medication, Poverty, [more]
  •  
IT, Utilities, Energy, [more]
Street Insider, KGWN TV, Healthcare Sector and Stocks Analysis from Seek..., [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Financings of the Fortnight Navigates Sequester... [Published The IN VIVO Blog - Feb 21 2013]
With several IPO hopefuls now in registration and a very odd venture round raised by a San Diego biotech, there was plenty of financing news to chew on the past couple weeks. But we’re sailing in a different direction for this fortnight’s most interesting ...
4 Healthcare Stock Stories for Wednesday Wellness [Published Wall St. Cheat Sheet - Jan 23 2013]
Johnson & Johnson  ( NYSE:JNJ ): Current price $72.79 Johnson & Johnson said that it will present its Medical Devices & Diagnostics division strategy for accelerating growth during its yearly Business Review. MD&D comprised around 41 percent of the ...
Telik announces FDA orphan drug designation of ... [Published PBR - News - Jan 14 2013]
Telik has announced notification of FDA orphan drug designation to ezatiostat HCL (Telintra) for the treatment of myelodysplastic syndrome (MDS). ...
4 Healthcare Stock Stories for Investor Wellbeing [Published Wall St. Cheat Sheet - Jan 11 2013]
Johnson & Johnson ( NYSE:JNJ ): Closing price $72.35 On Thursday, an FDA advisory panel okayed J&J’s canagliflozin, a drug for diabetes that could be the first in a new class of domestic drugs to treat the disease, although several panel members ...
1

Press Releases

sort by: Date | Relevance
Telik Announces First Quarter 2013 Financial Re... [Published Financial Services - May 10 2013]
Research and Markets: Mantle Cell Lymphoma - Pi... [Published Business Wire - Apr 18 2013]
Telik Announces Fourth Quarter And 2012 Year En... [Published PR Newswire: Financial Services - Mar 15 2013]
Telik Announces Preliminary Agreement On Design... [Published PR Newswire: Health - Jan 22 2013]
Telik Announces Orphan Designation Of Telintra®... [Published PR Newswire: Policy & Public Interest - Jan 12 2013]
1 2
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.